Frontiers in Psychiatry (Apr 2024)

The utility of PET imaging in depression

  • Shashi B. Singh,
  • Atit Tiwari,
  • Maanya R. Katta,
  • Riju Kafle,
  • Cyrus Ayubcha,
  • Cyrus Ayubcha,
  • Krishna H. Patel,
  • Yash Bhattarai,
  • Thomas J. Werner,
  • Abass Alavi,
  • Mona-Elisabeth Revheim,
  • Mona-Elisabeth Revheim

DOI
https://doi.org/10.3389/fpsyt.2024.1322118
Journal volume & issue
Vol. 15

Abstract

Read online

This educational review article aims to discuss growing evidence from PET studies in the diagnosis and treatment of depression. PET has been used in depression to explore the neurotransmitters involved, the alterations in neuroreceptors, non-neuroreceptor targets (e.g., microglia and astrocytes), the severity and duration of the disease, the pharmacodynamics of various antidepressants, and neurobiological mechanisms of non-pharmacological therapies like psychotherapy, electroconvulsive therapy, and deep brain stimulation therapy, by showing changes in brain metabolism and receptor and non-receptor targets. Studies have revealed alterations in neurotransmitter systems such as serotonin, dopamine, GABA, and glutamate, which are linked to the pathophysiology of depression. Overall, PET imaging has furthered the neurobiological understanding of depression. Despite these advancements, PET findings have not yet led to significant changes in evidence-based practices. Addressing the reasons behind inconsistencies in PET imaging results, conducting large sample size studies with a more standardized methodological approach, and investigating further the genetic and neurobiological aspects of depression may better leverage PET imaging in future studies.

Keywords